# A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

> **NCT02186119** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 151 (actual)

## Conditions studied

- Macular Edema

## Interventions

- **DRUG:** abicipar pegol
- **DRUG:** ranibizumab
- **OTHER:** sham procedure

## Key facts

- **NCT ID:** NCT02186119
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2015-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02186119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02186119, "A Study of Abicipar Pegol in Patients With Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02186119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*